Orient Pharma Co., Ltd. (TPEX:4166)

Market Cap	7.49B
Revenue (ttm)	1.22B
Net Income (ttm)	107.37M
Shares Out	223.04M
EPS (ttm)	0.48
PE Ratio	69.79
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	74,757
Average Volume	67,068
Open	33.50
Previous Close	33.85
Day's Range	32.75 - 34.10
52-Week Range	24.75 - 50.70
Beta	-0.13
RSI	60.14
Earnings Date	Apr 22, 2025

About Orient Pharma

Orient Pharma Co., Ltd. engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson’s and Alzheimer’s diseases; and products for the treatment of sialorrhea, tuberculosis, and attention deficit hyperactivity disorder. It is also developing drug delivery technologies, such as multi-stages-controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 173
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4166

Financial Performance

In 2024, Orient Pharma's revenue was 1.22 billion, an increase of 37.41% compared to the previous year's 889.91 million. Earnings were 107.37 million, an increase of 381.76%.